Qiagen and LabCorp collaborate to provide innovative companion diagnostics of cancer patients

Qiagen and LabCorp have collaborated to provide innovative companion diagnostics of cancer patients, such as Qiagen’s Day-One Lab Readiness program. LabCorp will be able to provide physicians and patients with faster access to new, genomically targeted drugs that are becoming increasingly important therapies for a growing variety of cancers.

LabCorp is the latest company to join the program, and its expertise in the commercial use of companion diagnostics will help a broader range of patients gain access to innovative tools for precision medicine. Building on the US Food and Drug Administration’s modernized regulatory approach, the program enables molecular diagnostic labs to begin implementing the activities necessary to prepare for commercial launch of new drugs and IVD tests once FDA approval is obtained.

LabCorp’s participation in Qiagen’s network of laboratory partners will contribute to ensuring testing readiness for a portfolio of new companion diagnostics, including tests based on next-generation sequencing (NGS) and qualitative polymerase chain reaction, being prepared for launches in 2019 and 2020 in several countries around the world. As more biomarkers and new technologies are used to develop in-vitro diagnostics, companion diagnostic testing is becoming increasingly complex. LabCorp’s extensive experience in these areas is a strong complement to Qiagen’s personalized health collaborations with leading pharmaceutical companies. Assays for multiple indications, including novel companion diagnostics across a range of cancers including lung, breast, colorectal, bladder, and eventually pan-tumor disease areas, are in LabCorp’s Day-One Readiness program.